Product Center
-
Influenza virus subunit vaccine (adjuvant) IND application approved
2024-10-30Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) jointly applied for a Class I new drug "Influenza Virus Subunit Vaccine (Adjuvant)" IND application, which has been approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration. The approval of this vaccine marks the completion of the full coverage of the company's subunit influenza vaccine product pipeline for trivalent and quadrivalent influenza virus subunit vaccines, providing the most accurate selection for different age groups and different demand groups.
Read More -
The application for the marketing of trivalent influenza virus subunit vaccine has been accepted!
2024-10-08Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）has received acceptance from the Drug Evaluation Center (CDE) of the China National Medical Products Administration for its application to market the "6-35 month old trivalent influenza virus subunit vaccine" and the "3-year-old and above trivalent influenza virus subunit vaccine". This acceptance marks the final sprint stage of the first domestic full dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!
Read More -
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants
2024-08-26On August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）, made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice".
Read More -
Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou
2024-08-14Recently, the Science and Technology Bureau of Taizhou City announced the first batch of offshore innovation centers for enterprises, and Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） wholly-owned subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) Successfully obtained recognition.
Read More
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
